Arvinas Inc (ARVN)
Healthcare
Biotechnology
8.00 $
-3.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Arvinas Inc (ARVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.5% of the shares are freely tradable; institutional investors hold 83.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
83.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
7.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
86.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
8.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
65Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 11.21 | 7,229,603 | -15.6 | 12/31/2025 |
| BlackRock Inc | 10.54 | 6,797,584 | -7.2 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 6.03 | 3,889,628 | +0.0 | 03/31/2026 |
| D. E. Shaw & Co LP | 5.64 | 3,638,567 | -1.4 | 03/31/2026 |
| Pfizer Inc | 5.36 | 3,457,815 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.17 | 2,689,362 | +0.0 | 03/31/2026 |
| TCG Crossover Management, LLC | 3.70 | 2,387,461 | -10.5 | 03/31/2026 |
| Armistice Capital, LLC | 3.07 | 1,978,000 | +9.9 | 03/31/2026 |
| Two Sigma Investments LLC | 2.84 | 1,832,114 | +84.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.98 | 1,920,682 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.